<DOC>
	<DOC>NCT00151398</DOC>
	<brief_summary>The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.</brief_summary>
	<brief_title>Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Diagnosis of probable AD according to the NINCDSADRDA criteria. Able to give informed consent. Patient` s caregiver must consent to participate in the study. Use of medications for cognitive enhancement within 3 months of baseline. Significant neurologic disease other than AD that may affect cognition.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>